Clinical Review
Posterior Reversible Encephalopathy Syndrome as a Complication of Chemotherapy
Fed Pract. 2012 February;29(2):23
Author and Disclosure Information
Igor Sirotkin, MD; Behzad Mowlazadeh, MD; Alexander Sochet, MD; Bruce Kudryk, MD
Patient presented with seizures soon after starting chemotherapy for large B-cell lymphoma; magnetic resonance imaging confirmed posterior reversible encephalopathy syndrome.
Posterior reversible encephalopathy syndrome (PRES) is a neurological disorder that can present with headache, seizure, visual changes, paresis, and altered mental status. On diagnostic imaging, PRES is classically characterized by symmetrical hemispheric edema typically in the parietal and occipital regions.1
Recommended Reading
Clinical Topics
-
Study of beliefs about what causes cancer sparks debate -
Tips on Better Patients Communication Publish date: October 26, 2022 -
VA Center Dramatically Shrinks Wait Times for Bone Marrow Biopsies Publish date: October 19, 2022 -
In VA Oncology, Discussion Groups Are Transforming the Workplace Publish date: October 19, 2022 -
Burnout Is Rampant, But Oncologists Can Turn the Tide Publish date: October 10, 2022
Digital Edition
-
Cancer Data Trends 2023 Publish date: July 5, 2023 -
Cancer Data Trends 2022 Publish date: March 30, 2022 -
AVAHO 2021 Meeting Posters and Abstracts Publish date: September 22, 2021 -
Advances in Hematology and Oncology Publish date: September 3, 2021 -
Advances in Hematology and Oncology Publish date: May 20, 2021
Multimedia
-
Freefall: How Skydiving Is Like Cancer Surgery Publish date: June 1, 2021 -
A Pivotal Moment in Cancer Surgery, Captured on Film Publish date: April 30, 2021 -
Laparoscopic surgery survival outcomes on par with open approach in colorectal liver metastases Publish date: June 3, 2019
Conference Coverage
-
Registered Dieticians Sparse in VA Cancer Care Publish date: November 11, 2024 -
Study Finds Elevated Skin Cancer Risk Among US Veterans Publish date: October 28, 2024 -
Which Medication Is Best? VA Genetic Tests May Have the Answer Publish date: October 4, 2024 -
IMRT vs Proton Therapy for Early Prostate Cancer? Publish date: October 3, 2024 -
Head and Neck Cancer: Should Patients Get PEG Access Prior to Therapy? VA pilot study could help clinicians make better-informed decisions to head off malnutrition Publish date: September 27, 2024 -
Transgender Women and Prostate Cancer: It’s Complicated Publish date: September 23, 2024 -
Changes in Age-Related Mortality in Malignant Melanoma From 1999- 2022: A CDC Wonder Study -
Geographical Trends in Malignant Melanoma from 1999-2022: A CDC Wonder Study -
Implementation of an Intervention to Improve Efficiency and Accuracy of Data Entry into the Veterans Affairs Central Cancer Registry at the Lexington VA Healthcare System -
A Phase II Study With Androgen Deprivation Therapy and Up-Front Radiotherapy in High-Intermediate and High-Risk Prostate Cancer With Stereotactic Body Radiation Therapy to Pelvic Nodes and Concomitant Prostate Boost by Simultaneous Integrated Boost
CLL incidence by race and location
Question 1 of 5